MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MEDP • US58506Q1094

530.35 USD
-11.69 (-2.16%)
At close: Feb 9, 2026
504.69 USD
-25.66 (-4.84%)
After Hours: 2/9/2026, 8:14:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, MEDP scores 6 out of 10 in our fundamental rating. MEDP was compared to 58 industry peers in the Life Sciences Tools & Services industry. MEDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. MEDP has a decent growth rate and is not valued too expensively. With these ratings, MEDP could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • MEDP had positive earnings in the past year.
  • MEDP had a positive operating cash flow in the past year.
  • MEDP had positive earnings in 4 of the past 5 years.
  • Of the past 5 years MEDP 4 years had a positive operating cash flow.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 24.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 147.46%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 91.45%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 13.29%.
  • The 3 year average ROIC (38.75%) for MEDP is below the current ROIC(91.45%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 24.7%
ROE 147.46%
ROIC 91.45%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

  • MEDP has a better Profit Margin (18.36%) than 91.38% of its industry peers.
  • MEDP's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 21.50%, MEDP belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
  • MEDP's Operating Margin has improved in the last couple of years.
  • MEDP has a Gross Margin of 31.11%. This is in the lower half of the industry: MEDP underperforms 70.69% of its industry peers.
  • MEDP's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.5%
PM (TTM) 18.36%
GM 31.11%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
  • MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 7.59 indicates that MEDP is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 7.59, MEDP belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
  • MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.59
ROIC/WACC8.25
WACC11.08%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

  • MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of MEDP (0.57) is worse than 94.83% of its industry peers.
  • MEDP has a Quick Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MEDP has a Quick ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 93.10% of its industry peers.
  • The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.57
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.14% over the past year.
  • Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.30% on average per year.
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.03%

3.2 Future

  • MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.29% yearly.
  • Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 10.47% on average per year.
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue Next Year11.99%
Revenue Next 2Y10.2%
Revenue Next 3Y11.36%
Revenue Next 5Y10.47%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 34.66, which means the current valuation is very expensive for MEDP.
  • MEDP's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of MEDP to the average of the S&P500 Index (28.06), we can say MEDP is valued slightly more expensively.
  • With a Price/Forward Earnings ratio of 31.55, MEDP can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than the industry average as 62.07% of the companies are valued more expensively.
  • MEDP's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.86.
Industry RankSector Rank
PE 34.66
Fwd PE 31.55
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 60.34% of the companies in the same industry.
  • 84.48% of the companies in the same industry are more expensive than MEDP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.08
EV/EBITDA 27.36
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
  • MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.51
PEG (5Y)1.11
EPS Next 2Y10.52%
EPS Next 3Y10.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MEDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDPACE HOLDINGS INC

NASDAQ:MEDP (2/9/2026, 8:14:46 PM)

After market: 504.69 -25.66 (-4.84%)

530.35

-11.69 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09
Earnings (Next)04-20
Inst Owners87.1%
Inst Owner Change-0.63%
Ins Owners0.44%
Ins Owner Change-6.05%
Market Cap14.94B
Revenue(TTM)N/A
Net Income(TTM)433.00M
Analysts52.22
Price Target557.47 (5.11%)
Short Float %6.04%
Short Ratio5.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.27%
PT rev (3m)7.24%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)-0.09%
EPS NY rev (1m)0%
EPS NY rev (3m)5.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.91%
Valuation
Industry RankSector Rank
PE 34.66
Fwd PE 31.55
P/S 6.33
P/FCF 22.08
P/OCF 21.01
P/B 50.88
P/tB N/A
EV/EBITDA 27.36
EPS(TTM)15.3
EY2.88%
EPS(NY)16.81
Fwd EY3.17%
FCF(TTM)24.02
FCFY4.53%
OCF(TTM)25.25
OCFY4.76%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)3.51
PEG (5Y)1.11
Graham Number59.9
Profitability
Industry RankSector Rank
ROA 24.7%
ROE 147.46%
ROCE 108.09%
ROIC 91.45%
ROICexc 233.48%
ROICexgc N/A
OM 21.5%
PM (TTM) 18.36%
GM 31.11%
FCFM 28.7%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 120.93%
Cap/Sales 1.46%
Interest Coverage 250
Cash Conversion 132.81%
Profit Quality 156.3%
Current Ratio 0.57
Quick Ratio 0.57
Altman-Z 7.59
F-Score8
WACC11.08%
ROIC/WACC8.25
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.03%
Revenue Next Year11.99%
Revenue Next 2Y10.2%
Revenue Next 3Y11.36%
Revenue Next 5Y10.47%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.4%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%

MEDPACE HOLDINGS INC / MEDP FAQ

What is the fundamental rating for MEDP stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDP.


Can you provide the valuation status for MEDPACE HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.


What is the profitability of MEDP stock?

MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.


What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?

The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 34.66 and the Price/Book (PB) ratio is 50.88.


How financially healthy is MEDPACE HOLDINGS INC?

The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.